Europe Peptide Synthesis Market - By Product Type: Custom Peptides, API-grade Therapeutic Peptides, Cosmetic & Nutraceutical Peptides, Reagents & Kits for Peptide Synthesis; By Technology: Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid & Microwave-Assisted Synthesis; By Country: Germany, United Kingdom, France, Spain, Italy, Russia, Rest of Europe
1 | Market Overview
The European peptide synthesis market includes the production, modification, and commercialization of peptides for pharmaceutical, research, diagnostic, and cosmetic applications. Peptides, which are short chains of amino acids, have gained significant traction in therapeutics due to their high specificity, low toxicity, and ability to target previously undruggable protein interactions.
The region has emerged as a key hub for peptide therapeutics and custom synthesis, supported by robust R&D, a strong CDMO presence, and rising investments in oncology, metabolic, and infectious disease research. Demand is also increasing from the cosmetic and nutritional supplement sectors, where bioactive peptides are used for anti-aging and muscle recovery.
2 | Market Size and Forecast
|
Year |
Market Value (USD Million) |
Notes |
|
2019 |
420 |
Pharma and R&D were leading segments |
|
2024 |
640 |
CAGR 8.7% (2019–2024) |
|
2031 |
1,280 |
Projected CAGR 10.3% (2024–2031) |
3 | Drivers & Challenges
Drivers:
Challenges:
4 | Segment Insights
By Product Type:
By Technology:
5 | Regional Insights
6 | Competitive Landscape
Key players: Bachem AG, Polypeptide Group, CordenPharma, Thermo Fisher Scientific, Merck KGaA, AmbioPharm, BCN Peptides, GenScript, ProteoGenix.
Emerging trends include:
Need help?
Chat with our team in a minute.